相关实验视频
Updated: Sep 17, 2025

09:11
Assays for Validating Histone Acetyltransferase Inhibitors
Published on: August 6, 2020
6.6K
新型二胺酸衍生物对希斯脱乙酶的抑制作用 1 1
Jhawn G Saul1,2, Andrew E Huckleby1,2, Maia C Gugello2
1Department of Biochemistry and Microbiology at Oklahoma State University-Center for Health Sciences, College of Osteopathic Medicine, Tulsa, OK 74464, USA.
Frontiers in bioscience (Scholar edition)
|July 4, 2025
概括
化合物4表现出比化合物6更强烈的结合和抑制作用对基因素脱乙酶1 (HDAC1) 的作用. 这种选择性HDAC1抑制为开发新的癌症疗法提供了一个有希望的策略.
科学领域:
- 药用化学 医学化学
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 基因组脱乙酶1 (HDAC1) 是染色质重塑和转录抑制中的关键表观遗传调节剂.
- 选择性HDAC1抑制是癌症治疗的一个有希望的策略,它调节基因表达并诱导亡.
研究的目的:
- 设计和评估基于酸盐的新型HDAC1抑制剂.
- 评估化合物4和6对HDAC的结合亲和力,稳定性和抑制功效1.1.
主要方法:
- 用分子对接和分子动力学 (MD) 模拟来分析联结蛋白相互作用和复杂稳定性.
- 进行了酶抑制试验,以确定IC50值,并评估新型化合物的抑制功效.
主要成果:
- 这两种化合物都与HDAC1显著相互作用,包括疏水性接触,结合和协调.
- 化合物4在MD模拟中表现出更强的结合亲和力 (-6.2kcal/mol) 和更高的稳定性,相比于化合物6 (-5.7kcal/mol).
- 化合物4表现出较高的抑制作用,IC50为2.96 ± 0.4μM,而化合物6的4.76 ± 0.5μM为4.76 ± 0.5μM.
结论:
- 与化合物6相比,化合物4显示了增强的结合亲和力,稳定性和对HDAC1的酶抑制.
- 化合物4是开发用于癌症治疗的新型选择性HDAC1抑制剂的有希望的主要候选者.
相关概念视频
Histone Modification
14.1K
The histone proteins have a flexible N-terminal tail extending out from the nucleosome. These histone tails are often subjected to post-translational modifications such as acetylation, methylation, phosphorylation, and ubiquitination. Particular combinations of these modifications form “histone codes” that influence the chromatin folding and tissue-specific gene expression.
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone...
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone...
14.1K
Spreading of Chromatin Modifications
8.5K
The histone proteins in the nucleosomes are post-translationally modified (PTM) to increase or decrease access to DNA. The commonly observed PTMs are methylation, acetylation, phosphorylation, and ubiquitination of lysine amino acids in the histone H3 tail region. These histone modifications have specific meaning for the cell. Hence, they are called "histone code". The protein complex involved in histone modification is termed as "reader-writer" complex.
Writers
The writer...
Writers
The writer...
8.5K
Indirect-Acting Cholinergic Agonists: Mechanism of Action
2.0K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
2.0K
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
573
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
573
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
666
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
666
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K

